AstraZeneca will delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing on the New York Stock Exchange, the company announced Tuesday.

The transition will take effect after market close on January 30, 2026, with trading on the NYSE expected to begin on February 2.

AstraZeneca will retain its “AZN” ticker symbol during the move.

Under the harmonized structure, AstraZeneca will transition from trading American Depositary Shares, which currently represent ordinary shares on a two-for-one basis, to a direct listing of its $0.25 ordinary shares.

This shift aims to simplify the company’s multi-market trading setup.